Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America (GASPAR)

February 11, 2025 updated by: Latin American Cooperative Oncology Group
Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region. The study aims to create a Latin American multicenter database to analyze epidemiological, clinical, and pathological data, treatments, outcomes, and biological information from patients with gastric and pancreatic cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients diagnosed with gastric and gastroesophageal junction or pancreatic cancer after January 2019 at participating sites will be included. Data will be collected from medical records in selected centers that comprise different countries from Latin America. Data collection will begin on the time of site activation.

Patients recruited for this study will be identified in the participating sites. Data from clinical, demographic, and socioeconomic variables will be collected. Also, data on treatments performed and outcomes will be abstracted. The patient data sources will be the medical records of the patients. Patients will continue to receive treatment and clinical evaluations for gastric and gastroesophageal junction or pancreatic cancer according to what is determined by their medical team, according to the usual standards of treatment and clinical practice of each center.

Study Type

Observational

Enrollment (Actual)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
    • Santa Fé
      • Santa Fe de la Vera Cruz, Santa Fé, Argentina
        • Instituto de Oncología San Gerónimo
  • Brazil
      • São Paulo, Brazil, 01.323-030
        • BP - A Beneficencia Portuguesa de São Paulo
      • São Paulo, Brazil, 01.509-001
        • A.C. Camargo Câncer Center
    • Bahia
      • Salvador, Bahia, Brazil, 41.950-640
        • ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brazil, 90.035-000
        • HMV - Hospital Moinhos de Vento
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brazil, 88.034-000
        • CEPON - Centro de Pesquisas Oncologicas

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with gastric and gastroesophageal junction or pancreatic cancer after January 2019.

Description

Inclusion Criteria:

  • ≥18 years
  • Histological diagnosis of gastric and gastroesophageal junction cancer (Cohort A) or histological diagnosis of pancreatic cancer (Cohort B);
  • Advanced disease diagnosis from January 2019: patients can be included prospectively. Advanced disease is defined as metastatic disease or locally advanced disease not amenable to curative therapy;
  • Availability of adequate medical data for data collection.

Exclusion Criteria:

  • Synchronous invasive tumor or second primary tumor in the last three years (except thyroid tumors or non-melanoma skin);
  • Nonepithelial histology in Cohort A: Sarcoma, GIST, lymphoma, and tumors of neuroendocrine origin;
  • Nonepithelial histology in Cohort B: Sarcoma, GIST, lymphoma, pancreatoblastoma, and tumors of neuroendocrine origin.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cohort A
120 patients with histological diagnosis of gastric and gastroesophageal junction cancer.
Other: Observational study
This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Cohort B
80 patients histological diagnosis of pancreatic cancer.
Other: Observational study
This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Describe the treatment patterns
Time Frame: During study duration (one year)
Describe the treatment patterns and outcomes of patients with gastric and gastroesophageal junction cancer in Latin America.
During study duration (one year)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Latin American Cooperative Oncology Group

Collaborators

Astellas Pharma Inc
Grupo Argentino de Investigación Clínica en Oncología (GAICO)

Investigators

  • Principal Investigator: Renata D´Alpino Peixoto, Latin American Cooperative Oncology Group

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 11, 2023

Primary Completion (Actual)

September 24, 2024

Study Completion (Actual)

September 24, 2024

Study Registration Dates

First Submitted

March 8, 2023

First Submitted That Met QC Criteria

June 20, 2023

First Posted (Actual)

June 29, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 11, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LACOG0222

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Clinical Trials on Observational study

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe